SCHEDULE 13G: Key Investors Disclose 4.99% Passive Stake in Pasithea Therapeutics Corp.

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have jointly disclosed a 4.99% beneficial ownership stake in Pasithea Therapeutics Corp. through a Schedule 13G filing, indicating a passive investment.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Pasithea Therapeutics Corp. common stock.
• As of May 12, 2025, the Reporting Persons collectively beneficially own 317,863 shares of Pasithea Therapeutics Corp. common stock.
• This ownership represents approximately 4.99% of the company's outstanding common stock.
• The shares beneficially owned consist of 285,714 shares issuable upon exercise of Intracoastal Warrant 1 and 32,149 shares issuable upon exercise of Intracoastal Warrant 2.
• The filing indicates that the Reporting Persons hold shared voting and dispositive power over all 317,863 shares.
• The beneficial ownership is a result of a Securities Purchase Agreement (SPA) executed with Pasithea Therapeutics Corp. on May 6, 2025.
• Warrants held by Intracoastal Capital LLC (Intracoastal Warrant 1, 2, 3, and 4) contain blocker provisions that prevent the holder from exercising them to the extent that such exercise would result in beneficial ownership exceeding 4.99% of the common stock.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 872,021 shares immediately following the SPA on May 6, 2025, and 586,307 shares as of May 12, 2025.

Sentiment

Score: 5

Explanation: The document is a factual, compliance-driven disclosure of beneficial ownership. It is neutral in tone and does not contain information that would significantly alter the perceived financial health or strategic direction of the company, beyond the fact of a new investment.

Positives

• The filing indicates that a group of investors, including Intracoastal Capital LLC, has made an investment in Pasithea Therapeutics Corp. through a Securities Purchase Agreement, which can be a positive signal of investor confidence.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests that the investors do not intend to seek control or influence the management of the issuer, which can provide stability.

Negatives

• The beneficial ownership includes shares issuable upon the exercise of warrants, which could lead to future dilution for existing shareholders if and when these warrants are fully exercised.

Risks

• Potential future dilution of existing shareholders if the warrants held by Intracoastal Capital LLC are exercised, increasing the total number of outstanding shares.
• The presence of blocker provisions in the warrants, while preventing immediate control issues, also limits the immediate upside for the investors by capping their beneficial ownership at 4.99%.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a standard regulatory disclosure for passive investors who acquire a beneficial ownership stake between 5% and 20% in a publicly traded company. It reflects an investment decision by a specific group of investors in Pasithea Therapeutics Corp., but does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a new significant passive investor group provides transparency regarding the company's ownership structure. The potential for future dilution from warrant exercise is noted.

Key Dates

Keywords

SEC filing, Schedule 13G, beneficial ownership, Pasithea Therapeutics Corp., common stock, warrants, passive investment, Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC, equity stake